Genetically Engineered Pig Kidney Keeps Patient Off Dialysis for 9 Months, Setting New Xenotransplantation Record

A genetically engineered pig kidney has kept a kidney-failure patient off dialysis for approximately nine months, marking a major milestone for human xenotransplantation and strengthening the case for engineered animal organs as a potential bridge to human transplantation.

The patient, Tim Andrews, became the first reported recipient to live for nine months with a genetically engineered pig kidney before subsequently receiving a human donor kidney. His experience, conducted at Massachusetts General Hospital in collaboration with eGenesis, has been published in The Lancet.

The development comes as the shortage of human donor organs continues to constrain transplantation access in the United States.

eGenesis’ Genetically Engineered Kidney Reaches a New Milestone

The kidney, known as EGEN-2784, was developed by U.S. biotechnology company eGenesis as part of its program to create human-compatible engineered organs.

According to eGenesis, five patients have received EGEN-2784 kidneys under an FDA-authorized Expanded Access program since March 2024. Three patients achieved sustained kidney function for more than eight months without dialysis.

Andrews’ experience is particularly important because the genetically engineered kidney functioned as a bridge to a subsequent human kidney transplant, rather than being considered a permanent replacement.

Harvard Medical School and Mass General Brigham reported that Andrews received the genetically engineered kidney before later receiving a donated human kidney in January 2026. His case represents the longest dialysis-free survival following porcine kidney xenotransplantation in a living human and the first documented transition from a pig kidney to a human kidney.

Why the Breakthrough Matters

Kidney failure creates an enormous demand for transplantation.

According to the U.S. Health Resources and Services Administration’s Scientific Registry of Transplant Recipients (SRTR), 143,982 adult candidates were listed for kidney transplantation in 2024, while 49,249 adults were newly added to the kidney waiting list, a record annual number.

The broader U.S. solid-organ transplant waiting list contained 167,230 unique patients in 2024, with 70,600 patients added during that year.

These figures highlight the potential importance of technologies that could provide an alternative source of transplantable organs.

However, xenotransplantation is still an investigational technology. A successful individual case does not establish long-term safety, efficacy, or regulatory approval.

How EGEN-2784 Is Genetically Engineered

eGenesis uses multiple categories of genetic modifications to make the pig kidney more compatible with the human body.

According to the company, EGEN-2784 incorporates three major classes of modifications:

1. Elimination of Three Glycan Antigens

The modifications remove three pig glycan antigens associated with hyperacute immune rejection.

2. Addition of Seven Human Transgenes

Seven human genes are inserted to help regulate immune responses, inflammation, coagulation compatibility, and complement activation.

3. Inactivation of Endogenous Retroviruses

The company also inactivates endogenous retroviruses within the pig genome as part of its approach to addressing potential safety concerns.

Together, these modifications are intended to improve organ compatibility and reduce biological barriers between the pig kidney and human recipient.

From Expanded Access to a Formal Clinical Trial

The next major milestone for eGenesis is moving from individual Expanded Access procedures to a formal clinical-development program.

The U.S. FDA has cleared a Phase 1/2/3 RESTORE trial evaluating EGEN-2784 in 33 patients with kidney failure who are between 50 and 70 years old and waitlisted for a human donor kidney.

eGenesis expects the RESTORE study to begin in the first quarter of 2027.

The company’s 2025 IND clearance previously supported a Phase 1/2/3 study designed to evaluate safety, tolerability, and efficacy at 24 weeks after transplantation in dialysis-dependent patients aged 50 or older who were on the kidney-transplant waiting list.

This transition is strategically important because the future of xenotransplantation will depend on reproducible outcomes across a larger patient population rather than individual compassionate-use successes.

eGenesis Pipeline Extends Beyond the Kidney

The company’s pipeline is not limited to kidney transplantation.

eGenesis is also developing EGEN-5784 ELC, a genetically engineered porcine liver intended for use with the OrganOx extracorporeal liver cross-circulation system in patients with acute-on-chronic liver failure and decompensated liver function in intensive-care settings. The FDA has cleared an IND for the program.

This creates a broader strategic opportunity for eGenesis: developing a platform for engineered organs rather than a single transplant product.

The company’s technology platform focuses on genetic engineering, donor production, high-biosecurity facilities, donor testing, and regulatory-compliant release testing.

Competitive Landscape: Xenotransplantation Enters a New Phase

eGenesis is operating in a rapidly developing xenotransplantation ecosystem.

Potential competitors and collaborators include organizations working on genetically modified pig organs, transplantation immunology, gene editing, organ preservation, and cross-circulation technologies.

The competitive landscape includes companies and research groups developing:

• Gene-edited pig kidneys
• Gene-edited pig hearts
• Gene-edited pig livers
• Immunosuppression strategies
• Organ preservation technologies
• Biosecure animal-production systems
• CRISPR-based genetic engineering platforms

The competitive advantage may ultimately depend not only on whether an engineered organ can function in a human but also on whether the company can produce organs consistently, demonstrate safety, establish scalable manufacturing and donor-production infrastructure, and satisfy regulators.

Patent and Intellectual Property Competition

Intellectual property will become increasingly important as xenotransplantation moves toward commercial development.

Competitive IP areas can include:

• Genetic-editing methods
• Specific gene modifications
• Donor-animal genetics
• Immunomodulatory transgenes
• Retrovirus inactivation
• Organ-production processes
• Donor screening
• Transplantation protocols
• Immunosuppression regimens
• Organ preservation
• Manufacturing and quality-control processes

For companies entering the field, patent landscaping and freedom-to-operate analysis will become increasingly important.

However, the existence of patents in a particular technology area does not by itself establish infringement or commercial exclusivity. A detailed patent assessment requires claim-level legal analysis.

GTM Strategy: Xenotransplantation Is Different From a Conventional Drug Launch

The commercialization strategy for engineered organs will likely differ significantly from conventional pharmaceutical launches.

A future GTM strategy would need to address several stakeholders simultaneously:

Patients → Transplant centers → Surgeons → Nephrologists → Regulators → Payers → Organ-production facilities

The first commercial opportunity may focus on patients with severe kidney failure who are on transplant waiting lists and face prolonged dialysis.

Potential Initial Positioning

Rather than positioning a xenotransplant as simply a replacement for human transplantation, companies could initially emphasize the potential role of an engineered organ as:

A bridge for selected patients awaiting a human donor organ.

The Andrews case provides an important proof-of-concept for this strategy because the patient subsequently received a human kidney.

Launch Strategy: Evidence Will Drive Adoption

For an engineered-organ product, launch readiness will depend heavily on clinical evidence.

A potential commercialization roadmap could include:

Phase 1: Clinical Validation

Demonstrate safety, kidney function, dialysis independence, and patient outcomes in controlled clinical studies.

Phase 2: Transplant-Center Development

Build relationships with leading transplant centers and establish standardized surgical and post-transplant protocols.

Phase 3: Manufacturing and Donor Scale-Up

Develop sufficient high-biosecurity donor-animal capacity and quality systems to support clinical and commercial demand.

Phase 4: Regulatory Strategy

Generate evidence addressing immune response, infection risk, graft durability, patient outcomes, and manufacturing consistency.

Phase 5: Payer and Health-Economic Strategy

Demonstrate whether xenotransplantation could reduce long-term costs associated with dialysis, hospitalization, transplantation delays, and complications.

The Economics Could Be a Critical Commercial Question

Kidney transplantation is not only a clinical issue; it is also a health-economic challenge.

A successful engineered kidney that reduces or eliminates dialysis for an extended period could potentially change the economics of kidney-failure care.

However, this should be treated as a future hypothesis rather than an established economic outcome.

Future studies will need to assess:

• Cost of engineered-organ production
• Surgical costs
• Immunosuppression costs
• Monitoring requirements
• Hospitalization
• Graft survival
• Dialysis avoidance
• Subsequent transplantation
• Long-term patient outcomes

A health-economic model comparing dialysis vs human transplantation vs xenotransplantation as a bridge could become increasingly important for payers and healthcare systems.

What Investors and Biopharma Companies Should Monitor

The next several years could provide important signals for the xenotransplantation industry.

Key indicators include:

• RESTORE trial initiation
• Number of participating transplant centers
• Patient enrollment
• 24-week kidney function
• Dialysis independence
• Rejection events
• Infection and safety signals
• Duration of graft function
• Subsequent human transplantation outcomes
• Regulatory interactions
• Manufacturing scale
• Donor-animal production capacity
• Additional xenotransplantation programs
• Partnerships and licensing activity

The transition from five Expanded Access recipients to a 33-patient clinical trial will be particularly important for assessing whether the early results can be reproduced systematically.

What This Means for the Future of Transplant Medicine

The nine-month dialysis-free outcome does not mean genetically engineered pig kidneys are ready for routine clinical use.

Instead, it represents an important clinical proof-of-concept.

The most significant finding may be that a genetically engineered pig kidney could potentially maintain kidney function long enough to serve as an interim treatment while a patient waits for a human organ.

That could create an entirely new transplantation paradigm:

Dialysis → Engineered pig kidney → Human donor kidney

rather than the conventional:

Dialysis → Human donor kidney

For patients facing prolonged waits, that distinction could be clinically meaningful.

How Towards Healthcare Can Support Xenotransplantation Strategy

The rapid development of xenotransplantation creates significant opportunities for biotech companies, investors, pharmaceutical companies, medical-device companies, and healthcare organizations.

Towards Healthcare Research & Consulting can support organizations evaluating this emerging field through:

Competitive Intelligence

Track:

• eGenesis
• Competing xenotransplantation programs
• Gene-editing companies
• Organ-preservation technologies
• Transplant-center partnerships
• Clinical milestones

Pipeline Intelligence

Monitor:

• Preclinical programs
• IND clearances
• Clinical trials
• Phase transitions
• Trial enrollment
• Regulatory milestones
• Pipeline expansion

Patent & Technology Intelligence

Analyze emerging IP landscapes across:

• CRISPR editing
• Pig genetic modifications
• Immunomodulation
• Retrovirus inactivation
• Donor production
• Organ preservation

GTM Strategy

Identify high-value customer and stakeholder segments across:

• Transplant centers
• Hospitals
• Healthcare systems
• Payers
• Biopharma companies
• Biotechnology companies

Launch Strategy

Develop evidence-based strategies around:

• Market entry
• Clinical adoption
• KOL engagement
• Transplant-center targeting
• Competitive positioning
• Payer communication

Healthcare Market Intelligence

Towards Healthcare can combine clinical-trial intelligence, competitor analysis, regulatory monitoring, technology intelligence, patent landscaping, and commercial research to help organizations understand where emerging transplantation technologies could create future opportunities.

Bottom Line

Tim Andrews’ nine-month experience with a genetically engineered pig kidney represents a significant milestone in xenotransplantation.

The case demonstrates that an engineered porcine kidney can potentially provide sustained kidney function and dialysis independence while preserving the possibility of a later human kidney transplant.

At the same time, the technology remains investigational. The next major test will be the FDA-cleared 33-patient RESTORE Phase 1/2/3 study, expected to begin in Q1 2027.

With 143,982 adult candidates on the U.S. kidney transplant waiting list in 2024, according to SRTR, the clinical need for additional transplant options remains substantial.

The evolution of EGEN-2784 will therefore be closely watched not only by transplant physicians and patients but also by biotech investors, regulators, healthcare systems, gene-editing companies, and pharmaceutical industry strategists.

For organizations seeking to understand the competitive landscape, pipeline evolution, patent environment, GTM opportunities, and commercialization strategy surrounding xenotransplantation, Towards Healthcare provides research-driven healthcare intelligence designed to support better strategic decisions.